Nektar Therapeutics is a clinical-stage immunology company developing immunomodulatory medicines that target regulatory T cells and other immune pathways. Its lead candidate, rezpegaldesleukin (REZPEG), is in Phase 3 development for moderate-to-severe atopic dermatitis.
Phase 3 ZENITH AD registrational trials of rezpegaldesleukin in atopic dermatitis
Planned first-in-human study of NKTR-0165
A jury awarded Nektar Therapeutics $90 million in damages after siding with the biotech, which accused Eli Lilly of botching an analysis of their formerly partnered autoimmune drug.
President and Chief Executive Officer